RA Capital Healthcare Fund LP 4
4 · Mineralys Therapeutics, Inc. · Filed Mar 31, 2026
Research Summary
AI-generated summary of this filing
Mineralys (MLYS) RA Capital Management Buys 369,000 Shares
What Happened
- RA Capital Management, L.P. (an investment adviser linked to a board director) reported purchases of Mineralys Therapeutics (MLYS) common stock. The filings show 310,700 shares bought on 2026-03-27 at a weighted average price of $23.67 (≈ $7.35M) and 58,300 shares bought on 2026-03-30 at a weighted average price of $24.16 (≈ $1.41M). Total acquired: 369,000 shares for roughly $8.76 million.
- These were purchases (transaction code P), which are generally viewed as a more informative “buy” signal than routine sales, though no motivation is stated.
Key Details
- Transaction dates and prices:
- 2026-03-27 — 310,700 shares @ weighted avg $23.67 (reported price range $23.31–$24.01) — ~$7,354,269.
- 2026-03-30 — 58,300 shares @ weighted avg $24.16 (reported price range $23.88–$24.39) — ~$1,408,528.
- Total: 369,000 shares acquired for ≈ $8,762,797.
- Shares owned after transaction: Not specified in the Form 4 filing.
- Holdings: The filing notes shares are held directly by RA Capital Healthcare Fund, L.P. and Nexus Fund III, L.P.; RA Capital Management is the adviser to those funds.
- Beneficial ownership: The adviser, its GP, the funds and certain individuals disclaim beneficial ownership except to the extent of any pecuniary interest.
- Filing timeliness: Form 4 was filed on 2026-03-31; based on the transaction dates (3/27 and 3/30) the filing appears to be timely.
Context
- This is institutional trading by an investment manager associated with a board member (Dr. Derek DiRocco is noted as a partner of the adviser and serves on the issuer’s board). It reflects purchases by funds advised by RA Capital rather than direct trades by an individual executive.
- The filing includes weighted-average price footnotes and price ranges; the reporting persons offered to provide details of individual trade prices on request. This was a straightforward purchase disclosure (no option exercises, gifts, or tax-withholdings reported).
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director
Transactions
- Purchase
Common Stock
[F1][F2][F3]2026-03-27$23.67/sh+310,700$7,354,269→ 5,767,221 total(indirect: See footnotes) - Purchase
Common Stock
[F4][F2][F3]2026-03-30$24.16/sh+58,300$1,408,528→ 5,825,521 total(indirect: See footnotes)
Holdings
- 1,867,229(indirect: See footnotes)
Common Stock
[F3][F5]
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.31 to $24.01 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]Held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").
- [F3]RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.88 to $24.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F5]Held directly by Nexus Fund III.